The long-range goal of this research is to develop tools for reducing production of beta-amyloid, which is a neurotoxic peptide that is thought to play a key role in causing Alzheimer's disease. The two homologous proteins presenilin 1 and 2 (PS1 and PS2) appear to play an important role in the generation of beta- amyloid from its parent protein, amyloid precursor protein. Using fibroblasts lacking PS1, we have observed that elimination of PS1 interferes with amyloid precursor protein processing and reduces production of beta-amyloid. This suggests that inhibitors of PS1 might also reduce beta-amyloid production. Over-expression of PS2 (as well as PS1) is able to restore processing of amyloid precursor protein in fibroblasts lacking PS1, which suggests that PS2 also participates in the metabolism of amyloid precursor protein and production of beta-amyloid. In this proposal we will investigate the hypothesis that specific domains of PS1 and PS2 regulate the metabolism of amyloid precursor protein and production of beta-amyloid. In addition, we will investigate whether the same presenilin domains that are required in the metabolism of amyloid precursor protein also necessary for other activities associated with presenilins, such as the regulation of apoptosis, glycogen synthase kinase 3? and ?-catenin activity. We will perform our studies in neurons, which are important generators of beta-amyloid in the brain. In the first aim we will investigate whether PS1 regulates amyloid precursor protein metabolism in cortical neurons. In the second aim we will investigate whether PS2 regulates amyloid precursor protein metabolism in cortical neurons lacking PS1. In the third aim, we will determine whether mutation or deletion of specific protein domains in PS1 and PS2, generates a modified presenilin that inhibits amyloid precursor protein processing and reduces beta-amyloid production. Our studies of amyloid precursor protein processing in neurons lacking PS1 or PS2 will serve as models for identifying inhibitory presenilin constructs. Identification of mutant forms of presenilin that inhibit beta- amyloid production could lead to novel strategies for therapeutic intervention in Alzheimer's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
1R01AG017485-01A2
Application #
6382995
Study Section
Special Emphasis Panel (ZRG1-BDCN-3 (01))
Program Officer
Snyder, D Stephen
Project Start
2001-08-01
Project End
2005-07-31
Budget Start
2001-08-01
Budget End
2002-07-31
Support Year
1
Fiscal Year
2001
Total Cost
$337,382
Indirect Cost
Name
Loyola University Chicago
Department
Pharmacology
Type
Schools of Medicine
DUNS #
791277940
City
Maywood
State
IL
Country
United States
Zip Code
60153
Wolozin, B; Manger, J; Bryant, R et al. (2006) Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 185:63-70
Frasier, M; Walzer, M; McCarthy, L et al. (2005) Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol 192:274-87
Ved, Rina; Saha, Shamol; Westlund, Beth et al. (2005) Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 280:42655-68
Wolozin, Benjamin; Brown 3rd, James; Theisler, Catherine et al. (2004) The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug Rev 10:127-46
Frasier, Mark; Wolozin, Benjamin (2004) Following the leader: fibrillization of alpha-synuclein and tau. Exp Neurol 187:235-9
Snyder, Heather; Wolozin, Benjamin (2004) Pathological proteins in Parkinson's disease: focus on the proteasome. J Mol Neurosci 24:425-42
Brown 3rd, James; Theisler, Catherine; Silberman, Simone et al. (2004) Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem 279:34674-81
Wolozin, Benjamin (2003) Cyp46 (24S-cholesterol hydroxylase): a genetic risk factor for Alzheimer disease. Arch Neurol 60:16-8
Wolozin, B (2002) Cholesterol and Alzheimer's disease. Biochem Soc Trans 30:525-9
Palacino, J J; Murphy, M P; Murayama, O et al. (2001) Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion. J Biol Chem 276:38563-9